Monday, November 16, 2026
23.3 C
Bengaluru

Creador Bets Big on Indian Pharma with 7% La Renon Stake

In a significant development for the Indian pharmaceutical industry, Kuala Lumpur-based private equity firm Creador has acquired a 7% stake in Ahmedabad-headquartered La Renon Healthcare for ₹800 crore. This investment values La Renon at nearly ₹11,000 crore, marking a major milestone in the company’s rapid growth journey and reflecting robust investor confidence in India’s pharmaceutical sector.

Background of the Deal

The new transaction builds on La Renon’s earlier funding successes and sharp valuation rise. Post-deal, the promoter family led by Pankaj Singh retains a controlling 66% stake, while private equity investors including ChrysCapital, Peak XV Partners, A91 Partners, and Avendus collectively hold 34%. Specifically, the promoter family is selling about 5% of equity, with Peak XV offloading around 2% to accommodate the new investment.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

Topics

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

The Innovator’s Gene and the Generic’s Promise

A medicine must first be discovered. It must then...

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...
spot_img

Related Articles

spot_imgspot_img